Agilent Technologies Inc (NYSE:A) – Stock analysts at Jefferies Group cut their Q2 2018 earnings per share estimates for Agilent Technologies in a research report issued to clients and investors on Thursday. Jefferies Group analyst B. Couillard now anticipates that the medical research company will earn $0.63 per share for the quarter, down from their previous estimate of $0.64. Jefferies Group also issued estimates for Agilent Technologies’ Q4 2018 earnings at $0.74 EPS, FY2018 earnings at $2.68 EPS, Q1 2019 earnings at $0.73 EPS, Q2 2019 earnings at $0.73 EPS, Q3 2019 earnings at $0.73 EPS, Q4 2019 earnings at $0.77 EPS and FY2019 earnings at $2.95 EPS.
A has been the topic of several other reports. JPMorgan Chase & Co. upped their target price on Agilent Technologies from $75.00 to $80.00 and gave the company an “overweight” rating in a report on Thursday. Cowen reiterated a “hold” rating and issued a $70.00 target price on shares of Agilent Technologies in a report on Wednesday, November 22nd. Robert W. Baird reiterated a “buy” rating and issued a $72.00 target price on shares of Agilent Technologies in a report on Friday, November 24th. Evercore ISI began coverage on Agilent Technologies in a report on Wednesday, January 3rd. They issued an “outperform” rating and a $75.00 target price on the stock. Finally, Zacks Investment Research upgraded Agilent Technologies from a “hold” rating to a “buy” rating and set a $76.00 target price on the stock in a report on Tuesday, October 31st. Five investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. The company presently has a consensus rating of “Buy” and an average price target of $70.98.
Agilent Technologies (NYSE:A) last posted its quarterly earnings results on Wednesday, February 14th. The medical research company reported $0.66 EPS for the quarter, beating the Zacks’ consensus estimate of $0.58 by $0.08. Agilent Technologies had a return on equity of 17.70% and a net margin of 4.25%. The business had revenue of $1.21 billion during the quarter, compared to the consensus estimate of $1.16 billion. During the same quarter in the previous year, the firm earned $0.53 earnings per share.
In other Agilent Technologies news, CEO Michael R. Mcmullen sold 22,481 shares of the business’s stock in a transaction that occurred on Monday, November 20th. The stock was sold at an average price of $70.00, for a total value of $1,573,670.00. Following the transaction, the chief executive officer now directly owns 327,882 shares of the company’s stock, valued at $22,951,740. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, insider Patrick Kaltenbach sold 7,358 shares of the business’s stock in a transaction that occurred on Wednesday, November 22nd. The shares were sold at an average price of $69.28, for a total value of $509,762.24. Following the completion of the transaction, the insider now directly owns 72,862 shares in the company, valued at $5,047,879.36. The disclosure for this sale can be found here. Over the last three months, insiders sold 197,510 shares of company stock worth $13,922,776.
A number of institutional investors and hedge funds have recently modified their holdings of the business. BlackRock Inc. raised its position in shares of Agilent Technologies by 8.1% during the fourth quarter. BlackRock Inc. now owns 25,665,358 shares of the medical research company’s stock worth $1,718,808,000 after purchasing an additional 1,912,186 shares during the period. Renaissance Technologies LLC raised its position in shares of Agilent Technologies by 325.0% during the fourth quarter. Renaissance Technologies LLC now owns 2,370,200 shares of the medical research company’s stock worth $158,732,000 after purchasing an additional 1,812,500 shares during the period. Arrowstreet Capital Limited Partnership raised its position in shares of Agilent Technologies by 145.4% during the fourth quarter. Arrowstreet Capital Limited Partnership now owns 1,726,929 shares of the medical research company’s stock worth $115,652,000 after purchasing an additional 1,023,099 shares during the period. TimesSquare Capital Management LLC acquired a new position in shares of Agilent Technologies during the third quarter worth approximately $58,550,000. Finally, Bank of Montreal Can raised its position in shares of Agilent Technologies by 187.3% during the fourth quarter. Bank of Montreal Can now owns 742,001 shares of the medical research company’s stock worth $49,693,000 after purchasing an additional 483,721 shares during the period.
About Agilent Technologies
Agilent Technologies, Inc provides application focused solutions that include instruments, software, services and consumables for the entire laboratory workflow. The Company serves the life sciences, diagnostics and applied chemical markets. It has three business segments: life sciences and applied markets business, diagnostics and genomics business, and Agilent CrossLab business.
Receive News & Ratings for Agilent Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agilent Technologies and related companies with MarketBeat.com's FREE daily email newsletter.